VFA
ICPT

Virtus Fund Advisers’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Virtus Fund Advisers’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,459
Closed -$16.1K – 119
2023
Q2 		$16.1K Hold
1,459
– – 0.11% 98
2023
Q1 		$19.6K Buy
+1,459
New +$25.2K 0.14% 100
2017
Q4 		$908K Buy
+15,542
New +$980K 0.01% 305

Other funds holding ICPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Virtus Fund Advisers's ICPT Position: Q3 2023 in Review

Virtus Fund Advisers sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2023, closing a stake of 1,459 shares — an estimated $16.1K sold.

Virtus Fund Advisers first reported a position in ICPT in Q4 2017 and held it in 3 quarters. The position peaked at $908K in Q4 2017. 146 funds tracked by Wall St. Rank hold ICPT as of Q3 2023.

  • Virtus Fund Advisers reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Virtus Fund Advisers sold 1,459 Intercept Pharmaceuticals, Inc. shares in Q3 2023, an estimated $16.1K.
  • Virtus Fund Advisers first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
  • Virtus Fund Advisers's Intercept Pharmaceuticals, Inc. position peaked at $908K in Q4 2017.
  • 146 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2023.

Based on Virtus Fund Advisers's 13F filing for Q3 2023, filed 8 Nov 2023.